Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2013 3
2014 1
2015 3
2016 4
2017 2
2018 3
2019 4
2020 5
2021 3
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean takahata m (382 results)?
DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial.
Yoshihara F, Imazu M, Sakuma I, Hiroi Y, Hara H, Okazaki O, Ishiguro C, Izumi C, Noguchi T, Shiraiwa T, Nishioka N, Fujii K, Iwakura K, Tomonaga O, Kobayashi K, Takihata M, Yumoto K, Takase H, Himi T, Shimizu I, Murakami T, Wagatsuma K, Sato K, Hiramatsu T, Akabame S, Hata S, Asakura M, Kawabata T, Omae K, Ito S, Kitakaze M; DAPPER Investigators. Yoshihara F, et al. Among authors: takihata m. EClinicalMedicine. 2023 Nov 27;66:102334. doi: 10.1016/j.eclinm.2023.102334. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38192595 Free PMC article.
Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes.
Matsuba I, Takihata M, Takai M, Maeda H, Kubota A, Iemitsu K, Umezawa S, Obana M, Kaneshiro M, Kawata T, Takuma T, Takeda H, Machimura H, Mokubo A, Motomiya T, Asakura T, Kikuchi T, Matsuzawa Y, Ito S, Miyakawa M, Terauchi Y, Kanamori A. Matsuba I, et al. Among authors: takihata m. Diabetes Obes Metab. 2021 Dec;23(12):2614-2622. doi: 10.1111/dom.14508. Epub 2021 Aug 12. Diabetes Obes Metab. 2021. PMID: 34338409
Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Kobayashi K, Toyoda M, Hatori N, Saito N, Kanaoka T, Sakai H, Furuki T, Umezono T, Ito S, Suzuki D, Takeda H, Minagawa F, Degawa H, Yamamoto H, Machimura H, Chin K, Hishiki T, Takihata M, Aoyama K, Umezawa S, Minamisawa K, Aoyama T, Hamada Y, Suzuki Y, Hayashi M, Hatori Y, Sato K, Miyakawa M, Tamura K, Kanamori A. Kobayashi K, et al. Among authors: takihata m. Diabetes Technol Ther. 2021 Feb;23(2):110-119. doi: 10.1089/dia.2020.0165. Epub 2020 Aug 13. Diabetes Technol Ther. 2021. PMID: 32721227
Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models.
Kobayashi K, Toyoda M, Hatori N, Furuki T, Sakai H, Umezono T, Ito S, Suzuki D, Takeda H, Minagawa F, Degawa H, Yamamoto H, Machimura H, Chin K, Hishiki T, Takihata M, Aoyama K, Umezawa S, Minamisawa K, Aoyama T, Hamada Y, Suzuki Y, Hayashi M, Hatori Y, Sato K, Miyakawa M, Tamura K, Kanamori A. Kobayashi K, et al. Among authors: takihata m. J Diabetes Investig. 2021 Jan;12(1):74-81. doi: 10.1111/jdi.13318. Epub 2020 Jul 10. J Diabetes Investig. 2021. PMID: 32506833 Free PMC article.
Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study.
Matsuba I, Kanamori A, Takihata M, Takai M, Maeda H, Kubota A, Iemitsu K, Umezawa S, Obana M, Kaneshiro M, Kawata T, Takuma T, Takeda H, Machimura H, Mokubo A, Motomiya T, Asakura T, Kikuchi T, Matsuzawa Y, Ito S, Miyakawa M, Terauchi Y, Tanaka Y. Matsuba I, et al. Among authors: takihata m. Diabetes Technol Ther. 2020 Mar;22(3):228-234. doi: 10.1089/dia.2019.0372. Epub 2020 Feb 3. Diabetes Technol Ther. 2020. PMID: 32013567 Clinical Trial.
Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.
Kawata T, Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyanagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Kawata T, et al. Among authors: takihata m. J Clin Med Res. 2017 Jul;9(7):586-595. doi: 10.14740/jocmr3038w. Epub 2017 May 22. J Clin Med Res. 2017. PMID: 28611859 Free PMC article.
Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Matsuba I, Kawata T, Iemitsu K, Asakura T, Amemiya H, Ishikawa M, Ito S, Kaneshiro M, Kanamori A, Kubota A, Shinoda K, Takai M, Takuma T, Takihata M, Takeda H, Tanaka K, Matsuzawa Y, Machimura H, Minagawa F, Minami N, Mokubo A, Miyakawa M, Terauchi Y, Tanaka Y. Matsuba I, et al. Among authors: takihata m. J Diabetes Investig. 2020 Sep;11(5):1248-1257. doi: 10.1111/jdi.13248. Epub 2020 Apr 25. J Diabetes Investig. 2020. PMID: 32149469 Free PMC article.
27 results